SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Addeo Alfredo)
 

Sökning: WFRF:(Addeo Alfredo) > Selpercatinib in RE...

  • Illini, OliverKarl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria. (författare)

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN) : a retrospective analysis of patients treated through an access program

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2021-06-11
  • Sage Publications,2021
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-456145
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-456145URI
  • https://doi.org/10.1177/17588359211019675DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-178982URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Karl Landsteiner Institute for Lung Research and Pulmonary Oncology
  • Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Methods: A retrospective efficacy and safety analysis was performed on data from RET fusion-positive NSCLC patients who participated in a selpercatinib access program (named patient protocol) between August 2019 and January 2021. Results: Data from 50 patients with RET fusion-positive advanced NSCLC treated with selpercatinib at 27 centers in 12 countries was analyzed. Most patients were Non-Asian (90%), female (60%), never-smokers (74%), with a median age of 65 years (range, 38-89). 32% of the patients had known brain metastasis at the time of selpercatinib treatment. Overall, 13 patients were treatment-naive, while 37 were pretreated with a median of three lines of therapy (range, 1-8). The objective response rate (ORR) was 68% [95% confidence interval (CI), 53-81] in the overall population. The disease control rate was 92%. The median progression-free survival was 15.6 months (95% CI, 8.8-22.4) after a median follow-up of 9 months. In patients with measurable brain metastases (n = 8) intracranial ORR reached 100%. In total, 88% of patients experienced treatment-related adverse events (TRAEs), a large majority of them being grade 1 or 2. The most common grade > 3 TRAEs were increased liver enzyme levels (in 10% of patients), prolonged QTc time (4%), abdominal pain (4%), hypertension (4%), and fatigue/asthenia (4%). None of patients discontinued selpercatinib treatment for safety reasons. No new safety concerns were observed, nor where there any treatment-related death. Conclusions: In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was well tolerated.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Hochmair, Maximilian JohannesKarl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria. (författare)
  • Fabikan, HannahKarl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria. (författare)
  • Weinlinger, ChristophKarl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria. (författare)
  • Tufman, AmandaLMU Munchen, Klinikum Univ Muenchen, Med Klin & Poliklin, Mitglied Deutsch Zentrums Lungenforsch, CPC M, Munich, Bayern, Germany. (författare)
  • Swalduz, AurelieCtr Leon Berard, Lyon, France. (författare)
  • Lamberg, KristinaUppsala universitet,Lung- allergi- och sömnforskning,Uppsala Univ Hosp, Sweden(Swepub:uu)krila642 (författare)
  • Hashemi, Sayed M. S.Vrije Univ Amsterdam, Med Ctr, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands.,Department of Pneumology, Ordensklinikum Elisabethinen Linz, Linz, Austria (författare)
  • Huemer, FlorianLudwig Boltzmann Inst Lung Hlth, Dept Resp Care, Klin Penzing, Vienna, Austria. (författare)
  • Vikström, AndersLinkoping Univ Hosp, Pulm clin, Linkoping, Sweden.,Region Östergötland, Lungmedicinska kliniken US(Swepub:liu)andvi77 (författare)
  • Wermke, MartinTech Univ Dresden, Med Fac C G Carus, NCT UCC Early Clin Trial, Unit Dresden, Dresden, Germany. (författare)
  • Absenger, GudrunMed Univ Graz, Dept Oncol, Graz, Austria. (författare)
  • Addeo, AlfredoUniv Hosp Geneva, Oncol Dept, Geneva, Switzerland. (författare)
  • Banerji, ShantanuUniv Manitoba, Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB, Canada. (författare)
  • Calles, AntonioUniv Gregorio Maranon, Hosp Gen, Med Oncol Dept, Madrid, Spain. (författare)
  • Clarke, StephenRoyal North Shore Hosp, Med Oncol Unit, St Leonards, NSW, Australia. (författare)
  • Di Maio, MassimoUniv Turin, Dept Oncol, Turin, Italy.;Ordine Mauriziano Hosp, Med Oncol, Turin, Italy. (författare)
  • Durand, AliceUniv Lyon, France Univ Claude Bernard Lyon 1, Hosp Civils Lyon, Canc Inst Lyon,Louis Pradel Hosp,Resp Dept, Lyon, France. (författare)
  • Duruisseaux, MichaelHosp Civils Lyon, Canc Inst, Louis Pradel Hosp, Resp Dept, Lyon, France.;Canc Res Ctr Lyon, Oncopharmacol Lab, Lyon, France.;Univ Lyon, Univ Claude Bernard Lyon 1, Lyon, France. (författare)
  • Itchins, MalindaRoyal North Shore Hosp, Med Oncol Unit, St Leonards, NSW, Australia. (författare)
  • Kääränien, Okko-SakariKuopio Univ Hosp, Ctr Canc, Kuopio, Finland. (författare)
  • Krenn, FlorianLKH Hochsteiermark Standort Leoben, Abt Lungenkrankheiten, Leoben, Austria. (författare)
  • Laack, EckartStudiengesellschaft Hamatoonkol Hamburg, Hamburg, Germany. (författare)
  • de Langen, Adrianus JohannesNetherlands Canc Inst, Amsterdam, Netherlands. (författare)
  • Mohorcic, KatjaUniv Clin Goln, Med Oncol Unit, Golnik, Slovenia. (författare)
  • Pall, GeorgUniv Innsbruck Hosp, Dept Internal Med V Hematol Oncol, Innsbruck, Austria. (författare)
  • Passaro, AntonioEuropean Inst Oncol IRCCS, Div Thorac Oncol, Milan, Italy. (författare)
  • Prager, GeraldComprehens Canc Ctr Vienna, Dept Med I, Vienna, Austria. (författare)
  • Rittmeyer, AchimLKI Lungenfachklin Immenhausen, Dept Thorac Oncol, Immenhausen, Germany. (författare)
  • Rothenstein, JeffreyR.S. McLaughlin Durham Regional Cancer Center at Lakeridge Health, Adjunct Assistant Professor Queen’s University, Ontario, Canada (författare)
  • Schumacher, Michael (författare)
  • Woell, EwaldDepartment Internal Medicine, St. Vinzenz Krankenhaus Betriebs GmbH, Sanatoriumstr. 43, 6511 Zams, Austria (författare)
  • Valipour, ArschangDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna (författare)
  • Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria.Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY: Sage Publications131758-83401758-8359

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy